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Oral route gets the highest priority for the 
delivery of the drug as well as better patient compliance in 
case of self delivery dosage formulation. The aim of 
present investigation was undertaken with the objective of 
formulating sustain release formulation of Itopride 
hydrochloride for oral drug delivery. Itopride hydrochloride 
is highly water soluble prokinetic drug. 
Hydroxypropylmethylcellulose K4M (lower viscosity 
grade) and K100M (higher viscosity grade) were used as a 
matrix forming agents to control the release of drug. HPMC 
K4M and HPMC K100M were used individually as well as 
in combination with different proportion in the preparation 
of the Sustained release formulation. 32 factorial designs 
were applied to the polymer concentration that affects the 
drug release profile. Reduced equation for drug release at 
2hr,6hr,and10hrwere
2
1212 017.225.341.5644.37 XXXQ ,
2
1216 75.34.405.8367.72 XXXQ ,and 
21110 8.2633.28.5844.90 2 XXXXQ  
respectively. Optimized batch F019 shows good tablet 
properties like hardness(7-9kg/cm2), thickness(4.48mm), 
friability(0.024%),assay(99.3%) and nearly similar drug 
release profile to the targeted reference drug release profile 
and it was indicated by similarity factor (f2=86.04). 
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Oral route of drug administration is perhaps the 
most appealing route for the delivery of drugs. Of the 
various dosage forms administered orally, the tablet is one 
of the most preferred dosage forms because of its ease of 
manufacturing, convenience in administration, accurate 
dosing, stability compared with oral liquids, and because it 
is more tamperproof than capsules.[1-4] Sustained release 
drug system is “any drug or dosage form modification that 
prolongs the therapeutic activity of the drug.”5 Ideally a 
sustained release oral dosage form is designed to release 
rapidly some pre determined fraction of the total dose in to 
GI tract. This fraction (loading dose) is an amount of drug, 
which will produce the desired pharmacological response 
as promptly as possible and the remaining fraction of the 
total dose (maintenance dose) is then release at a constant 
rate.[5-6] Hypromellose (Hydroxypropylmethylcellulose) is 
widely used in oral, ophthalmic and topical pharmaceutical 
formulations.7 Itopride hydrochloride, a novel prokinetic 
agent is best candidate for Gastro esophageal reflux disease 
(GERD). Itopride 50mg is given thrice in a day along with 
Proton pump inhibitor.8  By developing the sustain release 
formulation of Itopride hydrochloride, the frequency of 
drug administration can be reduce to once only to obtain 
good therapeutic response. The prepared formulation is 
usually taken on an empty stomach about an hour before 
meals and efficient to overcome GERD for 24 hr. Sustain 
release formulation of Itopride hydrochloride gives better 
patient compliance by reducing dosage frequency. 
 
MATERIALS AND METHODS: 
Material 
 
Itopride hydrochloride was received as a gift 
sample from Cadila Healthcare ltd, Ankleshvar, India. 
Hydroxypropylmethylcellulose (HPMC) K4M and K100M 
were purchased from Dow Chemicals, India. 
Microcrystalline Cellulose (pH 102) was purchased from 
FMC Biopolymer, Shangai, China. Lactose (DCL 21) was 
purchased from DMV International, Veghel, Netherlands. 
Pregelatinize Starch was purchased from Colorcon Asia 
Pvt. Ltd, Mumbai, India. Colloidal silicon dioxide was 
purchased from Cabot sanmar Ltd., Chennai, India. 
Magnesium Stearate was purchased from Amishi drugs & 
Chemicals, Ahmedabad, India. 
 
Methods: 
Drug excipients compatibility study 
  
 API and excipients were been thoroughly mixed in 
predetermined ratio and passed through the 40# sieve. The 
blend was to be filled in transparent glass vials and were 
closed with gray coloured rubber stoppers and further 
sealed with aluminum seal and charged into stress 
condition at 25ºCº±2°C / 60%RH± 5 % RH and 40ºC±2°C / 
75%RH± 5 % RH. Similarly API was also kept at same 
condition as for the samples. Samples were withdrawn for 
analysis within two days of sampling date as per the 
compatibility study plan. Physical observation should be 
done at every week up to 1 month and DSC studies were 
carried out to determine the compatibility of excipients 
with the drug.9 
Full Factorial Design:  
 
After studying results from preliminary batches, 
32 full factorial designs were prepared as shown in table 1. 
In this design 2 factors are evaluated, each at 3 levels, and 
experimental trials are performed at all 9 possible 
Combinations. The amounts of matrixing agent, HPMC 
K4M (X1), HPMC K100M (X2) were selected as 








JPRHC       January 2010        Volume 2             Issue 1     75-83   
 
 
Preparation of Itopride HCl SR Tablets:  
 
Itopride HCl SR Tablets were prepared by direct 
compression technique as follow. Drug was passed through 
40# sieve. HPMC K4M & HPMC K100M was passed 
through 30# sieve. All the other ingredients were passed 
through 40 # sieve accept Mg Stearate which was passed 
through 60# sieve. Itopride HCl, Lactose DCL 21 & MCC 
Avicel pH102 were mixed in double cone blender for 
10minute at 18 RPM. Add polymer and colloidal silicon 
dioxide into above mixture and again mixed for 10minute 
at 18 RPM. Add Mg Stearate into above mixture and mixed 
it for 3minute at 18 RPM. The prepared blend was 
compressed (14/32 diameter, flat punches) using 16 station 
tablet compression machine (Cadmach, Ahmedabad, India). 
 
Evaluation of SR Tablets 
The tablet geometry was determined by a means 
of Digital vernier calipers. Five tablets were used, and 
average values were calculated. While the breaking 
strength (hardness) of five tablets was determined using the 
Benchsavertm Series type hardness tester and the average 
values were calculated. Twenty tablets of each formulation 
were checked visually for any discoloration or surface 
roughness in the tablet formulation. To study weight 
variation test, twenty tablets of the formulation were 
weighed using a Mettler Toledo electronic balance and the 
test was performed according to the official method. The 
friability of twenty tablets was measured by Roche 
friabilator for 4 minute at 25rpm for 100 revolutions. 
Accurately weigh twenty tablets placed into Roche 
friabilator for 100 revolutions than dedust the tablets and 
weigh.13 






Friability                                                 
(1) 
In-vitro dissolution profile of prepared Itopride HCl SR 
Tablets  
The release rate of Itopride HCl from SR tablets 
was determined using United State Pharmacopoeia (USP) 
XXIV dissolution testing apparatus II (paddle method). The 
dissolution test was performed using 900 ml of 0.1 N HCl 
(PH=1.2), at 37°C ± 0.5°C at 50rpm. A sample (10 ml) of 
the solution was withdrawn from the dissolution apparatus 
at different time interval. The samples were replaced with 
fresh dissolution medium of same quantity. Drug released 
were analyzed at 258 nm wavelength using 0.1N HCl as a 
reference standard by Shimadzu UV1700 Double beam 
Spectrophotometer, Shimadzu (Kyoto, Japan.).14 
 
Comparison of dissolution profiles by statistical analysis 
with marketed product 
The similarity factor (f2) was defined by CDER, 
FDA and EMEA as the “logarithmic reciprocal square root 
transformation of one plus the mean squared difference in 
percent dissolved between the test and the reference 
products”. Moore and Flanner give the model independent 
mathematical approach for calculating a similarity factor f2 
for comparison between dissolution profiles of different 
samples. The similarity factor (f2) given by SUPAC 
guidelines for modified release dosage form was used as a 
basis to compare dissolution profile. The dissolution 
profiles of products were compared using f2. The similarity 
factor is calculated by following formula.15 












                          (2) 
Where, n is the number of dissolution time points 
Rt – The reference profile at the time point t 
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Tt - The test profile at the same point. 
A value of 100% for the similarity factor suggests that the 
test and reference profiles are identical. Values between 50 
and 100 indicate that the dissolution profiles are similar 
whilst smaller values imply an increase in dissimilarity 
between release profiles.16 
Accelerated Stability study 
Reproduce large scale batch F019 in blister pack 
(PVDC – Alu blister packing), was placed for stability 
study at 40˚C/75% RH for 3 months. Sample was collected 
at every 1 month interval and evaluated for dissolution in 
0.1N HCl, USP- II paddle apparatus, 50rpm. F2 value was 
applied to stability study to show the effect of storage on 
in-vitro drug release of formulation.17 
RESULT AND DISCUSSION: 
Drug excipients compatibility study: 
From the DSC Study and physical observation it 
was concluded that there was no significant Drug- 
Excipient interaction found. There was no change in drug’s 
melting peak after the preparation of tablet. So we can 
conclude that drug and other excipients were compatible 
with each other in tablet dosage form. 
 
Evaluation of SR Tablets 
The prepared tablet formulations as shown in 
table.1 were evaluated for different parameters like 
hardness, friability, assay, weight variation. Results of 
these parameters were shown in table 2. Hardness of the 
prepared tablets was found in range of 6-8 KP. All the 
tablet formulations showed acceptable pharmacotechnical 
properties and complied with the in-house specifications 
for weight variation, drug content, hardness, and friability. 
The size and surface area were kept constant by adding 
required quantity of lactose as a diluent, as it is well known 
fact that the drug release is also dependent on the size and 
surface area of matrix tablets. 
 
In-Vitro Drug release study 
The drug release profiles were characterized by 
an initial burst effect Q2 i.e. initial 30-35% drug release 
required in 2 hrs. The biphasic release is often observed 
from hydrophilic matrix systems. As the release rate 
limiting polymer like HPMC changes from a glassy state to 
rubbery state, a gel structure is formed around the tablet 
matrix, which considerably decreases the release rate of 
drug since the drug has to diffuse through this gel barrier 
into bulk phase. The strength of the gel depends on the 
chemical structure and molecular size of the polymer. It is 
known that higher viscosity grade polymer i.e. HPMC 
K100M hydrates at faster rate and therefore, it is capable of 
forming gel structure quickly than a low viscosity grade 
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Table 1. Formula of Factorial batches 
 
 
Table 2. Evaluation of tablets of Factorial batches 
 
 


























F01 47.29 20.71 10.00 5.00 15.00 1.00 1.00 100.00 
F02 47.29 15.71 10.00 5.00 20.00 1.00 1.00 100.00 
F03 47.29 10.71 10.00 5.00 25.00 1.00 1.00 100.00 
F04 47.29 18.21 10.00 7.50 15.00 1.00 1.00 100.00 
F05 47.29 13.21 10.00 7.50 20.00 1.00 1.00 100.00 
F06 47.29 8.21 10.00 7.50 25.00 1.00 1.00 100.00 
F07 47.29 15.71 10.00 10.00 15.00 1.00 1.00 100.00 
F08 47.29 10.71 10.00 10.00 20.00 1.00 1.00 100.00 
F09 47.29 5.71 10.00 10.00 25.00 1.00 1.00 100.00 
Table 2. Evaluation of tablets of Factorial batches 
Factorial   Batches Hardness (kP) Thickness 
(mm) 
Friability (%) Avg. Wt. 
(mg) 
Assay (%) 
F01 7-8 4.66 0.045 351.3 99.8 
F02 7-9 4.47 0.104 352.1 100.2 
F03 6.5-8 4.43 0.128 350.1 100.1 
F04 7-8 4.57 0.059 349.9 98.8 
F05 7-8 4.58 0.002 350.4 98.7 
F06 7-9 4.48 0.029 350.3 99.3 
F07 7-9 4.41 0.019 351.2 99.4 
F08 7-8 4.64 0.019 350.2 98.4 
F09 7-8 4.62 0.052 350.4 99.3 
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Table 3. Effect of Independent variable on dependent variable by 3
2
 full    
              factorial design of Itopride HCl Sustained release matrix tablet 
Batch No. 
Independent variable Dependent variable 
X1 X2 Q2 (%) Q6 (%) Q10 (%) 
F01 -1 -1 43.2 79.4 94.3 
F02 -1 0 40.1 76.9 96.4 
F03 -1 +1 38.2 73.5 93.5 
F04 0 -1 40.1 75.2 90.4 
F05 0 0 37.8 72.0 89.8 
F06 0 +1 33.4 69.7 87.4 
F07 +1 -1 32.9 67.9 87.8 
F08 +1 0 31.0 60.7 85.8 
F09 +1 +1 25.1 52.9 75.8 
Independent Variables 
Real Value 
Low (-1) Medium (0) High (+1) 
HPMC K4 M (X1) 5.0% 7.5 % 10.0 % 
HPMC K100 M(X2) 15.0% 20.0 % 25.0 % 
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Fig. 1    Comparative dissolution profile of Factorial batches of F01 to F09 and innovator 
 
 
    















The drug release is significantly dependent on the 
proportion and type of the polymer used. HPMC K4M was 
responsible for initial burst effect and HPMC K100M was 
used to sustained drug release. Factorial batches formulated 
using combination of HPMC K4M and HPMC K100M of 
Itopride HCl SR tablet were evaluated for dissolution 
study. Data of drug release are graphically represented in 
figure 1. f2 value of F01 to F09 batches are 50.89, 57.53, 
67.45, 64.87, 75.85, 86.04, 82.81, 74.71, 46.18. F06 batch 
showing very good similarity to the innovator batch release 
profile. (86.04)  
Effect of Independent variable on dependent variable  
The factorial batches were prepared by using independent 
variable, concentration of HPMC K4M(X1 )and HPMC 
K100M(X2) and its effect were check on dependent 
variable like Q2, Q6, and Q10.Factorial batches of Itopride 
HCl sustained release matrix tablets were evaluated for the 
in-vitro drug release (table 3), the effect of the individual 
polymer and combination of the polymers were studied.                                                                                          
Accelerated Stability study 
Reproduce large scale batch F06 in blister pack (PVDC – 
Alu blister packing), was placed for stability study at 
40˚C/75% RH for 3 months. Sample was collected at every 
1 month interval and evaluated for dissolution in 0.1N HCl, 
USP- II paddle apparatus, 50rpm. f2 value was applied to 
stability study to show the effect of storage on in-vitro drug 
release of formulation. The results of accelerated stability 
studies were shown figure 2. 
CONCLUSION 
 Results of present study suggested that Itopride HCl 
Sustained release matrix tablet can be successfully 
formulated using combination of HPMC K4M (7.5%) and 
HPMC K100M (25%).  F06 Batch of Itopride HCL SR 
tablets were good in terms of tablet physical properties, 
minimum drug excipients incompatibility and nearly 
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